SCHEMBL3770107

SCHEMBL3770107

COc1ccccc1C(=O)N1CCN(CC(=O)N2CCN(C3CCC3)CC2)CC1

nearest known ligand 0.66

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.66
ALDH1A1 P00352 3/20 0.66
HTT P42858 1/20 0.58
GAA P10253 2/20 0.55
POLB P06746 1/20 0.55
CYP2C9 P11712 1/20 0.52
CYP2C19 P33261 1/20 0.52
MAPK14 Q16539 1/20 0.52
DRD3 P35462 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TYR P14679 1/20 0.51
TDP1 Q9NUW8 1/20 0.50
TSHR P16473 1/20 0.50
MEN1 O00255 1/20 0.49
MAPK1 P28482 1/20 0.49
KMT2A Q03164 1/20 0.49
MGLL Q99685 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3774589 0.91 KDM4E (0.64) KDM4EALDH1A1HTTGAAPOLB
SCHEMBL3775759 0.89 NPSR1 (0.54) KDM4EALDH1A1HTTNPSR1TDP1
SCHEMBL13005903 0.88 ALDH1A1 (0.52) KDM4EALDH1A1HTTGAADRD3
SCHEMBL3768032 0.88 KDM4E (0.52) KDM4EALDH1A1HTTPOLBTDP1
SCHEMBL3763243 0.88 KDM4E (0.51) KDM4EALDH1A1HTTDRD3NPSR1
SCHEMBL3774020 0.87 TSHR (0.54) KDM4EALDH1A1GAANPSR1TSHR
SCHEMBL3776862 0.87 KDM4E (0.50) KDM4EALDH1A1HTTDRD3NPSR1
SCHEMBL3767746 0.86 HSD11B1 (0.51) KDM4EALDH1A1MEN1KMT2AMGLL
SCHEMBL3772205 0.86 ALDH1A1 (0.50) KDM4EALDH1A1HTTTSHRMEN1
SCHEMBL3769405 0.86 KDM2B (0.54) KDM4EALDH1A1HTTGAATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-7851474-B2 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION (US) 2010-12-14 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
US-20070049571-A1 Dipiperazinyl ketones and related analogues NEUROGEN CORPORATION 2007-03-01 US disclosed
WO-2007016496-A2 DIPIPERAZINYL KETONES AND RELATED ANALOGUES NEUROGEN CORPORATION (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049571-A1 Dipiperazinyl ketones and related analogues HRH4, HRH3, HRH1 KDM4E 534/4885ALDH1A1 1210/4885HTT 608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.